BHPW
BIO icon

Beverly Hills Private Wealth’s Bio-Rad Laboratories Class A BIO Stock Holding History

Beverly Hills Private Wealth’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-803
Closed -$224K – 270
2026
Q1 		$224K Buy
+803
New +$231K 0.04% 314
2025
Q4 		– Sell
-868
Closed -$243K – 338
2025
Q3 		$243K Sell
868
-70
-7% -$19K 0.04% 297
2025
Q2 		$226K Sell
938
-75
-7% -$17.7K 0.04% 311
2025
Q1 		$247K Buy
1,013
+12
+1% +$3.61K 0.05% 300
2024
Q4 		$329K Sell
1,001
-129
-11% -$43.8K 0.07% 240
2024
Q3 		$378K Sell
1,130
-204
-15% -$64.8K 0.08% 225
2024
Q2 		$364K Buy
1,334
+111
+9% +$32.3K 0.08% 240
2024
Q1 		$423K Buy
1,223
+310
+34% +$102K 0.1% 223
2023
Q4 		$295K Sell
913
-170
-16% -$53.3K 0.08% 259
2023
Q3 		$388K Sell
1,083
-736
-40% -$284K 0.12% 191
2023
Q2 		$728K Buy
1,819
+946
+108% +$385K 0.12% 186
2023
Q1 		$418K Buy
873
+130
+17% +$60.9K 0.13% 173
2022
Q4 		$312K Buy
+743
New +$300K 0.14% 171

Other funds holding BIO

First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Beverly Hills Private Wealth's BIO Position: Q2 2026 in Review

Beverly Hills Private Wealth sold out of Bio-Rad Laboratories Class A (BIO) in Q2 2026, closing a stake of 803 shares — an estimated $224K sold.

Beverly Hills Private Wealth first reported a position in BIO in Q4 2022 and held it in 13 quarters. The position peaked at $728K in Q2 2023. 398 funds tracked by Wall St. Rank hold BIO as of Q2 2026.

  • Beverly Hills Private Wealth reported no remaining Bio-Rad Laboratories Class A position as of Q2 2026 after selling out during the quarter.
  • Beverly Hills Private Wealth sold 803 Bio-Rad Laboratories Class A shares in Q2 2026, an estimated $224K.
  • Beverly Hills Private Wealth first reported a position in Bio-Rad Laboratories Class A in Q4 2022 and held it in 13 quarters.
  • Beverly Hills Private Wealth's Bio-Rad Laboratories Class A position peaked at $728K in Q2 2023.
  • 398 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2026.

Based on Beverly Hills Private Wealth's 13F filing for Q2 2026, filed 7 Aug 2026.